Press Releases
Please click the button below to download the article.
Payers Struggling to Manage Combination Use of Costly Prostate Cancer Therapies, Press Release, November 9, 2012
Tofacitinib to be positioned after anti-TNFs say payers based on FDA panel review, May 15, 2012
Oral Small Molecules for RA Face High Price-Sensitivity Hurdles, March 20, 2012
Payers Say Birth Control Mandate Will Increase Premiums, February 17, 2012
Payers Outlook for Lipitor Generic Strategy Not Rosy: Market Share Decline Coming Soon, December 2, 2011
Payers to Pharma: In Rheumatology, Innovations without Outcomes are Irrelevant, November 30, 2011
Real Endpoints Investment in Reimbursement Intelligence, November 15, 2011
Oncology Webinar Recap: High Cost of Cancer Drugs Forces Payors, Oncology Practices to Respond With New Payment Models, November 10, 2011
News and Articles
Please click the button below to download the article.
“BioMarin seeks approval to market another drug for rare disease” Marin Independent Journal, April 2013
“Beware the Increasing Cost And Number of Orphan Drugs” Managed Care, March, 2013
“The Importance of Prioritizing Palliative Care in Oncology: How Payers Can Assist Providers” Value-Based Care, March, 2013
“Hyperion Pricing On Ravicti Will Test Premium For Convenience In Orphan Market” The Pink Sheet, February, 2013
“Drug Makers See Profit Potential in Rare Diseases” Wall Street Journal, January, 2013
“How Much? Payers And The New Pfizer RA Pill” Pharmalot, January, 2013
“How Much? Managed Care and Combo Therapy for Prostate Cancer” Forbes, November, 2012
“ViewPoints: Sanofi blinks first in cancer price stand-off; what implications for industry/payer relationship in US?” FirstWord, November, 2012
“ViewPoints: Could Pfizer’s tofacitinib beat expectation and gain approval next month as a second-line therapy?” FirstWord, October, 2012
“Payers Collaborate with Providers to Adopt Oncology Pathways, New Care Delivery Models” American Health and Drug Benefits, August, 2012
“Spotlight On: Pfizer’s next blockbuster? – The outlook for tofacitinib” FirstWord, August, 2012
“Emerging Trends in Cancer Care: Health Plans’ and Pharmacy Benefit Managers’ Perspectives on Changing Care Models” American Health and Drug Benefits, July, 2012
“ViewPoints: Commercial prospects in the obesity market – physician and analyst observations” FirstWord, July, 2012
“Analysis: Drug costs become bigger issue in cancer care” Reuters, June, 2012
“Trends in RA Management: A Survey of Health Plans and Rheumatologists” Value-Based Care in Rheumatology, May, 2012
“Spotlight On: Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies” FirstWord, May, 2012
“Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers” American Health and Drug Benefits, March/April, 2012
“Why Pfizer’s Rheumatoid Arthritis Pill May Not Be A Sure Bet” Forbes, March, 2012
“Pfizer’s Rheumatoid Arthritis Pill: Not A Slam Dunk” Pharmalot, March, 2012
Payer Survey: Current Contraception Benefit Structure and Anticipated Impact of Mandated No-Cost Access for All Members , February, 2012
“What Managed Care Thinks of Pfizer And Its Lipitor Strategy” Forbes, December, 2011
“Review of Strategies to Enhance Outcomes for Patients with Type 2 Diabetes: Payers’ Perspective” American Health and Drug Benefits, September/October, 2011
“What Do Payers Want in Oncology Diagnostics? Insights From a National Survey of Top Commercial and Medicare Health Plans” American Health and Drug Benefits, August, 2011
“Payers expect Provenge sales to stay flat” FiercePharma, August, 2011
“Most Insurers Say Provenge Use Will Remain Flat” Pharmalot, August, 2011
“Payers Insights Into Future Oncology Management” Oncology Business Review, July, 2011
“Differing Views On The Eisai Breast Cancer Med” Pharmalot, July, 2011
“NCCN Still Recommends Avastin For Breast Cancer” Pharmalot, July, 2011
Publications
Please click the button below to download the article.
Biotechnology Entrepreneurship: From Science to Solutions – Chapter 9 “Roadmap to Reimbursement and Access”